Geisinger researchers awarded $7 million to study familial hypercholesterolemia
Projects to focus on risk factors, improving diagnosis and communication with patients
DANVILLE, Pa. – Geisinger researchers have been awarded two grants from the National Heart, Lung and Blood Institute, part of the National Institutes of Health, to study risk factors associated with familial hypercholesterolemia (FH) and ways to improve screening, diagnosis and communication with patients.
FH is a common genetic disorder that causes abnormally high cholesterol levels and affects about 1 in 250 people. Left untreated, FH can lead to vascular diseases including coronary artery disease, heart attack, stroke and arterial disease. Early diagnosis and treatment can dramatically reduce the risk of arterial disease and improve health outcomes.
Matt Oetjens, Ph.D., assistant professor at Geisinger’s Autism and Developmental Medicine Institute, was awarded $3.7 million for a genetic investigation of FH and its intersection with health disparities related to age, sex, race/ethnicity and rural environment. Dr. Oetjens’ study will determine how to use genetics to assess risk, improve care and develop effective ways to communicate risk information to patients and providers.
“This study is an important step toward translating new genetic findings about the causes of FH into improved patient care,” Dr. Oetjens said.
Laney Jones, Pharm.D., and Samuel Gidding, M.D., both of Geisinger’s Genomic Medicine Institute, were awarded $3.3 million to design and conduct a clinical trial to improve the diagnosis of FH in the primary care setting. The trial will assess the effectiveness of several strategies for improving FH diagnosis, including universal screening for specific age groups using diagnostic tools like lipid panels and genetic testing, initiating early treatment and studying patient health outcomes.
“An FH diagnosis is often made too late, many times after a premature heart attack,” Dr. Jones said. “Diagnosing FH in the primary care setting would optimize treatment for these people early in the course of the disease. Our long-term goal is to create an effective FH diagnosis program that is practical and sustainable in the real-world setting.”
The team plans to implement the trial over a two-and-half-year period in all Geisinger primary care sites starting in February 2023.
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 10 hospital campuses, a health plan with more than half a million members, a research institute and the Geisinger College of Health Sciences, which includes schools of medicine, nursing and graduate education. With more than 25,000 employees and 1,700+ employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.
For media inquiries:
Ashley Andyshak Hayes
Marketing & Communications